We and others have recently shown that CS-E, but not other CS forms, can function as a potent inhibitor of the Wnt/beta-catenin pathway in fibroblasts [8], [47] and breast cancer cells (Willis and Klüppel, unpublished results). Here, CTNNB1 is linked to breast carcinoma.